B+
Bull case
25%
Probability
Target price
$1.60
+79.7% vs current
BEAT
HeartBeamBNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$0.85
-4.5% vs current
B-
Bear case
25%
Probability
Target price
$0.35
-60.7% vs current
AI sentiment snapshot
Latest data as of 2026-04-17
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+49.5
Score
AI commentary
Sentiment remains cautiously constructive but monitoring-oriented. The deterministic prior is still positive, yet the most important new fact is the April 2026 equity raise, which improves immediate runway while reinforcing financing dependence and dilution risk [#8-K-2026-04-16]. Primary sources still support a real platform story through the first commercial customer, ALIGN-ACS enrollment, and Mount Sinai AI collaboration, but forward visibility is limited and the thesis has not graduated to a clean bullish call [#10-K-2026-03-12].
RankAlpha Sentiment Codex - 2026-04-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-31catalystApril equity raise reduces immediate funding cliff but locks in dilution overhangHigh impact
HeartBeam’s April 14, 2026 underwritten offering sold 12.5 million shares at $0.80, closed April 16, and is expected to generate about $10.0 million of gross proceeds, with proceeds earmarked for commercialization, the extended-wear patch, heart attack detection, AI, and working capital [#8-K-2026-04-16]. That helps address the 10-K’s going-concern warning and sub-$5 million year-end cash balance, but it also resets the near-term price reference and underscores continuing dependence on equity funding [#10-K-2026-03-12].
2026-09-30eventClearCardio rollout must progress from LOI to repeatable commercial adoptionHigh impact
The 10-K says HeartBeam announced ClearCardio as its first commercial customer, with an initial staged rollout, subscription fee per patient, and only a Letter of Intent in place while the parties negotiate a definitive agreement [#10-K-2026-03-12]. The next meaningful proof point is whether this becomes a signed broader deployment and a usable reference account rather than a single early pilot-like relationship.
2026-12-31catalystClinical and AI programs can widen the platform story, but timelines remain earlyHigh impact
HeartBeam disclosed first-patient enrollment in the 100-patient ALIGN-ACS study for heart attack assessment and also announced a strategic AI collaboration with Mount Sinai to develop personalized cardiac AI on its platform [#10-K-2026-03-12]. These programs support a broader home-cardiac-monitoring narrative, but monetization, regulatory timing, and clinical validation are still uncertain.
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-17 • Updated nightlySource: Internal modelMethodology